8-K: Palatin Technologies Secures $340,000 Private Placement Amidst NYSE American Delisting

Palatin Technologies, Inc. has completed a private placement of convertible preferred stock and warrants, raising $340,000, following its delisting from the NYSE American due to low stock price.

Summary

• Palatin Technologies, Inc. entered into a Securities Purchase Agreement on June 10, 2025, to sell securities in a private placement.
• The private placement involved the sale of 3,400 shares of newly designated Series D Convertible Preferred Stock, with a stated value of $100 per share, and Series I Common Stock Purchase Warrants.
• The Preferred Stock is initially convertible into up to 3,090,909 shares of Common Stock at an initial conversion price of $0.11 per share.
• The Warrants allow for the purchase of up to an aggregate of 6,181,818 shares of Common Stock at an exercise price of $0.11 per share.
• The private placement closed on June 13, 2025, generating gross proceeds of $340,000, which the company intends to use for general working capital purposes.
• Key participants in the private placement included the company's President and CEO, Chief Financial Officer and Chief Operating Officer, and two directors, indicating significant insider participation.
• The company's common stock was delisted from the NYSE American on May 7, 2025, due to a low selling price, and has since moved to trade on the Pink Market (May 8 June 6, 2025) and subsequently the OTCQB Market (since June 9, 2025) under the symbol PTNT.
• The Preferred Stock accrues dividends at a rate of 8% per annum, payable in cash or by accretion to the stated value, and has a liquidation preference.
• The Warrants become exercisable only after shareholder approval is obtained, as required by NYSE American rules, and expire five years after this approval date.
• The company is obligated to file a registration statement on Form S-3 within 30 calendar days to allow for the resale of the Conversion Shares and Warrant Shares, aiming for effectiveness within 60 to 90 days.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's delisting from a major exchange and the highly dilutive nature of the capital raise, despite securing necessary funding. The insider participation, while positive for confidence, also highlights the company's limited options for financing.

Positives

• The company successfully raised $340,000 in gross proceeds, providing capital for general working capital purposes.
• Significant participation from company management and directors in the private placement may signal their confidence in the company's future.

Negatives

• The company's common stock was delisted from the NYSE American due to a low selling price, indicating significant market challenges and a loss of a major exchange listing.
• The stock now trades on the OTCQB Market, which typically has lower liquidity and less visibility compared to national exchanges.
• The terms of the private placement, including a low conversion/exercise price of $0.11 per share for common stock equivalents, suggest substantial potential dilution for existing shareholders.
• The need for shareholder approval for the warrants to become exercisable introduces a contingency and potential delay for the full realization of the capital structure changes.

Risks

• The company's delisting from the NYSE American to the OTCQB Market poses risks related to reduced liquidity, investor interest, and potentially lower stock valuation.
• The securities issued in the private placement (Preferred Stock and Warrants) have not been registered under the Securities Act, relying on exemptions, which imposes restrictions on their resale.
• Future sales of Conversion Shares and Warrant Shares, once registered, could lead to significant dilution of existing common stock holdings.
• The company's ability to maintain its listing on the OTCQB Market and comply with its rules is an ongoing risk.
• Failure to obtain shareholder approval for the exercise of the Warrants could impact the intended capital structure and future financing options.
• The company's ability to achieve and maintain an effective registration statement for the resale of the underlying shares is crucial for the liquidity of the newly issued securities.

Future Outlook

Palatin Technologies plans to file a registration statement on Form S-3 within 30 calendar days of the agreement date to facilitate the resale of the Conversion Shares and Warrant Shares, aiming for effectiveness within 60 to 90 days. The company also intends to use the net proceeds from the private placement for general working capital purposes and will continue efforts to maintain its listing on the OTCQB Market.

Management Comments

• The participation of the President and CEO, Chief Financial Officer and Chief Operating Officer, and two directors in the private placement indicates their direct investment and commitment to the company's financial stability and future prospects.

Industry Context

This announcement reflects the challenges faced by smaller biotechnology companies, particularly those with a low stock price, in maintaining listings on major exchanges and securing financing. The reliance on private placements, especially with significant insider participation and terms that imply substantial dilution, is often characteristic of companies navigating financial distress or seeking to bridge funding gaps outside of traditional public market avenues. The move to the OTCQB Market is a common step for companies unable to meet the listing requirements of national exchanges.

Comparison to Industry Standards

• The delisting from NYSE American due to low selling price is a significant negative indicator, placing Palatin Technologies below the standards of companies listed on major national exchanges.
• The terms of the private placement, including a low conversion/exercise price relative to the stated value of the preferred stock and the high potential for dilution, are indicative of a distressed financing scenario, which is generally not aligned with the financing terms secured by healthier, well-capitalized industry peers.
• While insider participation can signal confidence, the necessity of such a private placement with management involvement, rather than a broader market offering, suggests limited access to conventional capital sources, contrasting with more robust funding rounds seen in successful biotech companies.

Corporate Governance

Related Party Transactions

• The private placement involved the sale of securities to Carl Spana (President and CEO), Stephen T. Wills (Executive Vice President, CFO, and COO), John K.A. Prendergast (Director and Chairman), and Alan W. Dunton (Director).

Stakeholder Impact

• Shareholders: Face significant potential dilution from the conversion of Preferred Stock and exercise of Warrants at a low price. The delisting to OTCQB may reduce liquidity and investor interest.
• Management/Directors: Their participation in the private placement demonstrates a direct financial commitment to the company, aligning their interests with its future success.

Next Steps

• The company is required to file a registration statement on Form S-3 (or other appropriate form) within 30 calendar days of June 10, 2025, for the resale of the Conversion Shares and Warrant Shares.
• The company will use commercially reasonable efforts to cause the registration statement to become effective within 60 days (or 90 days if subject to full SEC review) following the closing date of June 13, 2025.
• The company needs to obtain shareholder approval for the Warrants to become exercisable, as required by NYSE American rules (even though delisted, this approval is a condition for the warrants).

Key Dates

Recommendation

Keywords

Palatin Technologies, PTN, Private Placement, Convertible Preferred Stock, Warrants, SEC Filing, 8-K, OTCQB, NYSE American, Delisting, Capital Raise, Dilution, Securities Issuance